Ribavirin, an anti-viral agent, is a nucleoside analog and is used for the treatment of SARS-CoV infection. The mechanism of action of this drug includes that the drug inhibits the DNA and RNA replication, disrupting the synthesis of guanosine triphosphate by the inhibition of inosine monophosphate dehydrogenase enzyme [[131], [132], [133]]. 5′ triphosphate metabolite of ribavirin, which inhibits the virus's polymerase activity, viral capping inhibition, and induces lethal mutagenesis in the RNA genome of the virus, resulting in the anti-viral effect of ribavirin [134]. The route of drug administration includes aerosol, oral, and intravenous. This drug is used to treat SARS-CoV infection. It has resulted in severe adverse effects, including anemia in about 27–59% of tested patients, which further led to dreadful outcomes such as tissue hypoxia [[135], [136], [137], [138]]. Also, it elevated the levels of transaminases and resulted in hypocalcemia, hypomagnesemia, developed the risk of teratogenicity and bradycardia [139].